Rapid leukaemic evolution in a cutaneous blastic NK-cell lymphoma initially diagnosed as pseudolymphoma

Hematology. 2007 Apr;12(2):155-7. doi: 10.1080/10245330600938398.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antigens, CD / analysis
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor
  • Bleomycin / administration & dosage
  • CD4 Antigens / analysis
  • CD56 Antigen / analysis
  • Cyclophosphamide / administration & dosage
  • Diagnosis, Differential
  • Diagnostic Errors*
  • Disease Progression
  • Doxorubicin / administration & dosage
  • HLA-DR Antigens / analysis
  • Humans
  • Killer Cells, Natural / pathology*
  • Lymph Nodes / diagnostic imaging
  • Lymphoma, Non-Hodgkin / chemistry
  • Lymphoma, Non-Hodgkin / diagnosis*
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / pathology
  • Lymphoma, T-Cell, Cutaneous / diagnosis
  • Male
  • Neoplasm Proteins / analysis
  • Prednisone / administration & dosage
  • Proto-Oncogene Proteins c-bcl-2 / analysis
  • Pseudolymphoma / diagnosis*
  • Radiography
  • Skin Neoplasms / chemistry
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / drug therapy
  • Vincristine / administration & dosage

Substances

  • Antigens, CD
  • Biomarkers, Tumor
  • CD4 Antigens
  • CD56 Antigen
  • HLA-DR Antigens
  • Neoplasm Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Bleomycin
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP-B protocol